Caley Castelein - 15 Oct 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
Director
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
15 Oct 2025
Net transactions value
$0
Form type
4
Filing time
17 Oct 2025, 17:50:10 UTC
Previous filing
16 Jun 2025
Next filing
28 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Castelein Caley Director C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK /s/ Brad Middlekauff, Attorney-in-Fact 17 Oct 2025 0001355758

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRML Common Stock Gift $0 -522 -0.1% $0.000000 515,997 15 Oct 2025 Direct
holding TRML Common Stock 431,939 15 Oct 2025 By KVP Capital, LP F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Gives effect to in-kind distribution of shares by KVP Capital, LP ("KVP") to its limited partner for no consideration, subsequent to the Reporting Person's most recent filing, which represented a change in the form of the Reporting Person's ownership that was not required to be reported under Section 16.
F2 These shares are held by KVP. The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.